King's College London

Sickle Cell Disease (SCD) presents a significant global health challenge, particularly affecting individuals of Black ancestry. Pregnant individuals with SCD face heightened risks, including elevated maternal mortality rates and increased incidences of complications like preterm birth and intrauterine growth restriction. Addressing these challenges is crucial, especially given the substantial financial burden on healthcare systems.

While blood transfusions are the primary treatment during pregnancy, they pose risks and logistical challenges. Hydroxyurea, a medication with proven benefits for SCD management, is often discontinued during pregnancy due to concerns about fetal safety. However, existing data on its impact during pregnancy are limited.

Our research aims to bridge this knowledge gap by investigating how hydroxyurea affects pregnant mice with SCD. By administering doses similar to those used in human treatment, we seek to assess its impact on maternal health and offspring outcomes.

The insights gained from this study could have profound implications for clinical practice. If hydroxyurea proves safe and effective in our mouse model, it could revolutionize prenatal care for individuals with SCD. Maintaining hydroxyurea therapy during pregnancy could mitigate risks for both mother and baby, reducing complications and improving outcomes. Furthermore, this research has broader implications, particularly in regions where access to blood transfusions is limited. By offering an alternative treatment option, we could alleviate strain on healthcare systems and improve the quality of care for pregnant individuals with SCD worldwide.